THERATECHNOLOGIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 CAD | 0.00% |
|
-0.55% | -15.89% |
| Sales 2024 * | 120M 87.62M 7.02B | Sales 2025 * | 128M 93.64M 7.5B | Capitalization | 82.76M 60.5M 4.85B |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -4.39M -351M | Net income 2025 * | -13M -9.5M -761M | EV / Sales 2024 * | 0.69 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.65 x |
| P/E ratio 2024 * |
-11.4
x | P/E ratio 2025 * |
-7.52
x | Employees | 103 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Theratechnologies Inc.
More recommendations
More press releases
More news
| 1 week | -0.55% | ||
| Current month | -19.28% | ||
| 1 month | -6.25% | ||
| 3 months | -16.28% | ||
| 6 months | +41.73% | ||
| Current year | -15.89% |
1 week
1.75
1.90
1 month
1.752.27
Current year
1.623.43
1 year
1.225.84
3 years
1.2222.44
5 years
1.2231.92
10 years
1.2259.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Lévesque
CEO | Chief Executive Officer | 60 | 05/04/20 |
Philippe Dubuc
DFI | Director of Finance/CFO | 57 | 23/02/16 |
| Chief Tech/Sci/R&D Officer | 61 | 31/12/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Molson
BRD | Director/Board Member | 56 | 15/10/20 |
Frank Holler
BRD | Director/Board Member | 67 | 22/06/21 |
| Director/Board Member | 80 | 07/02/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.8 | 0.00% | 14,756 |
| 25/04/24 | 1.8 | -2.70% | 10,185 |
| 24/04/24 | 1.85 | -2.12% | 16,019 |
| 23/04/24 | 1.89 | +2.16% | 5,402 |
| 22/04/24 | 1.85 | +2.21% | 5,600 |
Delayed Quote Toronto S.E., April 26, 2024 at 09:00 pm
More quotes
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
Sector
Pharmaceuticals
Calendar
09/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.8
CAD
Average target price
8
CAD
Spread / Average Target
+344.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 60.46M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- TH Stock
